This is a single-site, randomized, acute dose-response study to determine whether STX209
produces a dose-dependent significant change in MEG target parameters compared to baseline as
well as compared to placebo treatment.
Phase:
Early Phase 1
Details
Lead Sponsor:
Children's Hospital of Philadelphia Timothy Roberts
Collaborators:
Clinical Research Associates, LLC Simons Foundation